Extended Data Table 1.
Follow-up duration calculated as time from randomization to the date of death or the database cutoff date, whichever was earliest
Follow-up duration | Pembrolizumab group | Placebo group |
---|---|---|
| ||
Intention-to-treat population | N=217 | N=217 |
Median,* months | 8.4 | 7.7 |
Range, months | 0.1–19.0 | 0.5–17.9 |
Efficacy population | N=133 | N=131 |
Median,* months | 11.1 | 10.4 |
Range, months | 2.2–19.0 | 0.5–17.9 |
Medians were calculated using the observation time method.